In populations with a high (≥14) median National Institute of Health Stroke Score (NIHSS), a normal finding of Thrombolysis in Brain Ischemia grade 5 (TIBI 5) in the artery of interest has been reported to be an unusual finding when transcranial ultrasound is performed during thrombolysis. In such instances, a stroke mimic can be suspected, but there are alternative pathophysiological explanations. In this case series, the median NIHSS was relatively low (5), and 33% (6/18) of the patients treated with thrombolysis had TIBI 5 in the artery of interest at the time of treatment initiation. These 6 patients had normal findings on the computerized tomography angiography. Only 33% (2/6) of these patients were stroke mimics, the remaining had either lacunar (n = 2) or cortical strokes (n = 2). These cortical stroke patients probably had a pretreatment recanalization marked by partial symptom regression before treatment onset. Compared to patients with TIBI <5 at baseline, the patients with TIBI 5 at baseline tended to be younger (p = 0.19, Mann-Whitney test) and more often have lacunar syndrome (p = 0.18, g2 test). Thus, among patients treated with thrombolysis and with a low median NIHSS, a finding of TIBI 5 is not unusual. This does not mean that the patient has a stroke mimic per se, and it tends to be more common among patients with lacunar syndrome than among patients with cortical syndromes. i 2014 S. Karger AG, Basel

Keywords:
Sonothrombolysis, Stroke, Thrombolysis, Thrombolysis in Brain Ischemia grade, Transcranial ultrasound
1.
Alexandrov AV, Sloan MA, Tegeler CH, Newell DN, Lumsden A, Garami Z, Levy CR, Wong LKS, Douville C, Kaps M, Tsivgoulis G; for the American Society of Neuroimaging Practice Guidelines Committee: Practice standards for transcranial Doppler (TCD) ultrasound. Part II. Clinical indications and expected outcomes. J Neuroimaging 2012;22:215-224.
2.
Tsivgoulis G, Alexandrov AV, Sloan MA: Advances in transcranial Doppler ultrasonography. Curr Neurol Neurosci Rep 2009;9:46-54.
3.
Alexandrov AV, Molina CA, Grotta JC, Garami Z, Ford SR, Alvarez-Sabin J, Montaner J, Saqqur M, Demchuk AM, Moye LA, Hill MD, Wojner AW; CLOTBUST Investigators: Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. N Engl J Med 2004;351:2170-2178.
4.
Demchuk AM, Burgin WS, Christou I, Felberg RA, Barber PA, Hill MD, Alexandrov AV: Thrombolysis in brain ischemia (TIBI) transcranial Doppler flow grades predict clinical severity, early recovery, and mortality in patients treated with intravenous tissue plasminogen activator. Stroke 2001;32:89-93.
5.
Chernyshev OY, Garami Z, Calleja S, Song J, Campbell MS, Noser EA, Shaltoni H, Chen CI, Iguchi Y, Grotta JC, Alexandrov AV: Yield and accuracy of urgent combined carotid/transcranial ultrasound testing in acute cerebral ischemia. Stroke 2005;36:32-37.
6.
Tsivgoulis G, Eggers J, Ribo M, Perren F, Saqqur M, Rubiera M, Sergentanis TN, Vadikolias K, Larrue V, Molina CA, Alexandrov AV: Safety and efficacy of ultrasound-enhanced thrombolysis: a comprehensive review and meta-analysis of randomized and nonrandomized studies. Stroke 2010;41:280-387.
7.
Alexandrov AV: Cerebrovascular Ultrasound in Stroke Prevention and Treatment, ed 2. West Sussex, John Wiley Sons Ltd, 2011.
8.
Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE 3rd; the TOAST Investigators: Classification of subtype of acute ischemic stroke definitions for use in a multicenter clinical trial. Stroke 1993;24:35-41.
9.
Tsivgoulis G, Sharma VK, Lao AY, Malkoff MD, Alexandrov AV: Validation of transcranial Doppler with computed tomography angiography in acute cerebral ischemia. Stroke 2007;38:1245-1249.
10.
Tsivgoulis G, Ribo M, Rubiera M, Vasdekis SN, Barlinn K, Athanasiadis D, Shahripour BR, Giannopoulos S, Stamboulis E, Harrigan MR, Molina CA, Alexandrov AV: Real-time validation of transcranial Doppler criteria in assessing recanalization during intra-arterial procedures for acute ischemic stroke: an international, multicenter study. Stroke 2013;44:394-400.
11.
Urra X, AriAo H, Llull L, Amaro S, Obach V, Cervera &#193;, Chamorro &#193;: The outcome of patients with mild stroke improves after treatment with systemic thrombolysis. PLoS One 2013;8:e59420.
12.
Strbian D, Piironen K, Meretoja A, Sairanen T, Putaala J, Tiainen M, Artto V, Rantanen K, H(ppFl( O, Kaste M, Lindsberg PJ; for the Helsinki Stroke Thrombolysis Registry Group: Intravenous thrombolysis for acute ischemic stroke patients presenting with mild symptoms. Int J Stroke 2013;8:293-299.
13.
Kim JT, Lee SH, Hur N, Jeong SK: Blood flow velocities of cerebral arteries in lacunar infarction and other ischemic strokes. J Neurol Sci 2011;308:57-61.
14.
Gujjar AR, William R, Jacob PC, Jain R, Al-Asmi AR: Transcranial Doppler ultrasonography in acute ischemic stroke predicts stroke subtype and clinical outcome: a study in Omani population. J Clin Monitor Comput 2011;25:121-128.
15.
Del Bene A, Palumbo V, Lamassa M, Saia V, Piccardi B, Inzitari D: Progressive lacunar stroke: review of mechanisms, prognostic features, and putative treatments. Int J Stroke 2012;7:321-329.
16.
The CLOBUST-ER trial. http://www.clinicaltrials.gov NCT01098981.
17.
The NOR-SASS trial. http://www.clinicaltrials.govNCT01949961.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.